Every year in January, the American Diabetes Association (ADA) comes out with new guidelines for managing diabetes. This year’s guidelines have a revolutionary new recommendation for patients with type 2 diabetes and a history of cardiovascular disease (e.g. heart attack, stroke, etc). This is based on exciting new research.
Any new diabetic medication must be studied to ensure that it is safe for the heart and does not increase the risk of cardiovascular disease. It turns out that 2 of these medications, Victoza (liraglutide) and Jardiance (empagliflozin), were found to actually decrease the risk of cardiovascular disease. Based on these findings, the FDA has given each of these medications a new indication with regard to cardiovascular disease. For Victoza, the new indication is to reduce the incidence of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. For Jardiance, the new indication is to reduce the incidence of cardiovascular death.
Based on these studies and the new indications for Victoza and Jardiance, the ADA now recommends that patients with type 2 diabetes and a history of cardiovascular disease be prescribed these medications. This is a true paradigm shift because up until now, no medication for diabetes has been shown to reduce the risk of cardiovascular disease. Give us a call at (561) 513-5100 or contact us to speak with your PBDES physician and discover if this treatment approach may be appropriate for you.